Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole | Zendy

Clara T. M. M. de Kanter | Zendy; Angela Colbers | Zendy; Maren I. Blonk | Zendy; C.P.W.G.M. Verwey-van Wissen | Zendy; B.J.J.W. Schouwenberg | Zendy; Joost P.H. Drenth | Zendy; David M. Burger | Zendy

Open Access

Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole

Author(s) -

Clara T. M. M. de Kanter,

Angela Colbers,

Maren I. Blonk,

C.P.W.G.M. Verwey-van Wissen,

B.J.J.W. Schouwenberg,

Joost P.H. Drenth,

David M. Burger

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt032

Subject(s) - boceprevir , omeprazole , medicine , pharmacokinetics , cmax , pharmacology , proton pump inhibitor , telaprevir , gastroenterology , hepatitis c virus , immunology , virus , ribavirin

Proton pump inhibitors (PPIs) can limit the solubility of concomitant drugs, which can lead to decreased absorption and exposure. Reduced efficacy can be a consequence and in the case of an antimicrobial agent this may contribute to development of resistance. Patients chronically infected with the hepatitis C virus can be treated with a boceprevir-containing regimen and it is relevant to know if interactions between PPIs and boceprevir exist. This study was designed to investigate the influence of a frequently used PPI, omeprazole, on the pharmacokinetics of boceprevir and vice versa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research